Clinical review report: AbobotulinumtoxinA (Dysport therapeutic) (Ipsen biopharmaceuticals Canada Inc.) indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older
The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the symptomatic treatment of lower-limb spasticity in pediatric patients two years of age and older
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, August 2018
|
Edition: | Final with redacations |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the symptomatic treatment of lower-limb spasticity in pediatric patients two years of age and older |
---|---|
Physical Description: | 1 PDF file (130 pages) illustrations |